Last reviewed · How we verify
Subject's habitual PGA monotherapy
PGA (prostaglandin analog) monotherapy reduces intraocular pressure by increasing uveoscleral outflow of aqueous humor.
PGA (prostaglandin analog) monotherapy reduces intraocular pressure by increasing uveoscleral outflow of aqueous humor. Used for Open-angle glaucoma, Ocular hypertension.
At a glance
| Generic name | Subject's habitual PGA monotherapy |
|---|---|
| Sponsor | Alcon, a Novartis Company |
| Drug class | Prostaglandin analog (PGA) |
| Target | Prostaglandin F (FP) receptor |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Prostaglandin analogs are agonists at prostaglandin F (FP) receptors located on the ciliary muscle bundle and trabecular meshwork. Activation of these receptors increases conventional and uveoscleral drainage of aqueous humor from the anterior chamber, thereby lowering intraocular pressure. This mechanism makes them effective first-line agents for glaucoma and ocular hypertension.
Approved indications
- Open-angle glaucoma
- Ocular hypertension
Common side effects
- Conjunctival hyperemia
- Iris pigmentation increase
- Eyelash growth (hypertrichosis)
- Periocular skin pigmentation
- Eye irritation/discomfort
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Subject's habitual PGA monotherapy CI brief — competitive landscape report
- Subject's habitual PGA monotherapy updates RSS · CI watch RSS
- Alcon, a Novartis Company portfolio CI